ZyVersa Therapeutics, Inc.
ZVSA
$0.1221
-$0.0079-6.08%
OTC PK
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -13.34% | 61.81% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -4.69% | 66.69% | |||
| Operating Income | 4.69% | -66.69% | |||
| Income Before Tax | 2.02% | -58.41% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 2.02% | -58.75% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 2.02% | -58.75% | |||
| EBIT | 4.69% | -66.69% | |||
| EBITDA | 4.69% | -66.55% | |||
| EPS Basic | 36.77% | -1.74% | |||
| Normalized Basic EPS | 36.76% | -1.52% | |||
| EPS Diluted | 36.77% | -1.74% | |||
| Normalized Diluted EPS | 36.76% | -1.52% | |||
| Average Basic Shares Outstanding | 54.95% | 56.02% | |||
| Average Diluted Shares Outstanding | 54.95% | 56.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||